BMS no se inhibe...compra Inhibitex por $2.5bn.

Bristol-Myers Squibb has acquired clinical stage biopharmaceutical company Inhibitex in a deal that boosts its presence in hepatitis C.

Inhibitex’s lead compound is the oral nucleotide polymerase (NS5B) inhibitor INX-189, which is in phase II trials in combination with pegylated interferon and ribavirin for chronic hepatitis C.

The deal, which cost BMS approximately $2.5bn, is the latest phase in the pharma company’s much-touted 'string of pearls' approach to drug development.
This relies on complementing internal R&D with a suite of alliances, partnerships and acquisitions in its core therapeutic areas and Georgia, US-based Inhibitex is the newest 'pearl' in the string of more than a dozen deals BMS has made since 2007. (Ver)